ClinicalTrials.gg
RecruitingNCT07948811Updated Nov 19, 2026

A Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever

A Phase 3 interventional study of Acetaminophen 650 mg/Naproxen Sodium 220 mg and Placebo tablet in Fever, sponsored by Kenvue Brands LLC. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Kenvue Brands LLC · Phase 3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 118 studies in Fever with a site in United States — 14 open to participants now, 15 under way, 1 of them phase 3. Fever · United States.

Planned enrollment
18th of 84
292 · median 102
Started
2026
with 2 others
Phase 3
25 of 118
1 open now
Primary completion
2027-10
later than 10 of 12 live
Registered
117th of 118
by date

Among the 118 studies in Fever with a site in United States, this one is the 18th largest by planned enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 in phase 3, reaches primary completion later than 10 of the 12 other live ones, and was the 117th registered.

Fever

439 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

14 of the 118 studies in Fever with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Fever with a site in United States, or all of them as a file.
02

Study summary

To evaluate the antipyretic efficacy of a single dose of a fixed combination of acetaminophen/naproxen sodium, compared with placebo.

Read the detailed description

This will be a randomized, single-dose, double-blind, placebo-controlled, parallel-group study to evaluate the antipyretic efficacy and safety of a fixed-dose combination (FDC) of acetaminophen/naproxen sodium in adult subjects with endotoxin-induced fever, compared to placebo.

The study will be conducted in two study phases (Phase A and Phase B), with the intent of Phase A being for endotoxin dose evaluation and the intent of Phase B being to evaluate the investigational product (IP)/placebo.

Subjects enrolled in Phase A will not be included in Phase B, nor will data from these subjects be included in the statistical analysis. Phase A will be completed prior to starting Phase B. Data from Phase A will be reviewed by the Phase A Data Review Team to determine if a satisfactory endotoxin dosing regimen has been achieved. Once a satisfactory dosing regimen is determined, separate subjects will be enrolled in Phase B. Once the endotoxin induced qualifying fever (temperature ≥38.1°C) is established, eligible subjects will be randomized in a 1:1 allocation to receive a single dose of either the IP or the placebo

03

Conditions studied

  • Fever

Browse trials for

Keywords

  • Fever Analgesics
  • Acetaminophen
  • Naproxen Sodium
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

Subjects must meet all of the following inclusion criteria in Sections A and B to be eligible for enrollment into the study:

A) Assessed at Screening Visit (Visit 1):

  1. Has a (BMI) of 17.5 to 37.0 (inclusive) for subjects who are 18 to 40 years old or a BMI of 17.5 to 35.0 (inclusive) for subjects who are 41 to 55 years old.
  2. Healthy, defined as having no abnormalities or medical conditions identified by a detailed medical history; full physical examination; blood pressure, respiratory rate, and heart rate measurements; 12-lead ; and clinical laboratory tests conducted at Visit 1.
  3. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests at Visit 1.
  4. Has a negative QuantiFERON-TB Gold Plus tuberculosis, surface antigen, antibody, and (HIV) test based on clinical laboratory tests at Visit 1.
  5. Has a negative urine drug screening test and a negative breath alcohol test conducted at Visit 1.
  6. Has adequate veins, as determined by visual inspection at Visit 1, for IV catheter insertion.
  7. Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, procedures, and subject responsibilities specified within the form (ICF).
  8. Has provided written informed consent before participating in any study specific procedures.
  9. Agrees to follow requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.
  10. Is a non-tobacco/nicotine user or previous user who completely stopped smoking/using any form of tobacco or nicotine-containing product at least 6 months before Visit 1.

B) Assessed at Day 0 and Day 1 (of Visit 2):

  1. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination conducted on Day 0 (and symptoms-driven physical exam on Day 1, if applicable); blood pressure, respiratory rate, and heart rate measurements (conducted on Day 0 and Day 1); 12-lead ECG (conducted on Day 1), and clinical laboratory tests (conducted on Day 0).
  2. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests on Day 0.
  3. Has a negative* urine drug screening test and a negative breath alcohol test conducted on Day 0 (*including a negative result for THC. A positive urine drug screening test for medications that have been prescribed to the subject are acceptable).
  4. Has adequate veins, as determined by visual inspection on Day 0, for IV catheter insertion.
  5. Has an oral temperature between 36.37 °C and 37.21 °C as measured on Day 0 and Day 1. If the subject's oral temperature is not between 36.37 °C and 37.21 °C after a single reading, then 2 additional oral temperature readings will be obtained within a 30-minute period. The average of these 3 consecutive temperature readings must be between 36.37 °C and 37.21 °C, with the highest value within 0.1 °C of the lowest temperature value.
  6. Agrees to follow contraception requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.

C) Assessed Once Qualifying Fever Established (Randomization Criteria; Phase B Only) Subjects must meet all of the following criteria following endotoxin administration in order to be randomized during Phase B. Subjects who do not meet these criteria will not be randomized.

  1. Has not experienced an allergic reaction or exaggerated systemic response to administration of endotoxin, as determined by the PI or medically qualified designee.
  2. Has not required medical management of an AE that includes an antipyretic treatment.
  3. Has developed an oral temperature of at least 38.1 ºC after endotoxin dosed per study guidelines.

Exclusion Criteria (to be assessed at Visit 1, Day 0 of Visit 2, and Day 1 of Visit 2).

Subjects must not meet any of the following exclusion criteria to be eligible for enrollment into the study

  1. Has a pregnant or nursing partner or a partner who is currently trying to become pregnant.
  2. Is self-reported to be unable to swallow whole large tablets or capsules.
  3. Has participated in any interventional clinical studies within 30 days before Visit 1.
  4. Is related to the persons involved directly or indirectly with the conduct of this study (PI, Sub-Investigator(s), study coordinators, other site personnel, employees/contractors of Kenvue or its subsidiaries, employees of IQVIA) at Visit 1.
  5. Has a known allergy or to acetaminophen, naproxen, naproxen sodium, ibuprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs) (including acetylsalicylic acid or other salicylates), any of the inactive ingredients in the products, ondansetron, or the endotoxin used in the study.
  6. Has a history of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the PI or designee, in the last five years.
  7. To be assessed at Day 0: Has consumed alcohol within 48 hours prior to Day 0.
  8. To be assessed at Day 0: Has consumed caffeine or other methylxanthine containing products (e.g., chocolate bars or chocolate beverages, coffee, tea, cola, or caffeinated energy drinks) within 24 hours prior to Day 0.
  9. To be assessed at Day 0: Has experienced cold/flu symptoms (i.e., runny nose, cough, pain, and/or fever) within 2 weeks prior to Day 0.
  10. To be assessed at Day 0: Has used prescription or nonprescription drugs within 5 half-lives prior to Day 0.
  11. To be assessed at Day 0: Has used any drug that may impact gastric motility, such as glucagon-like peptide-1 (GLP-1) medication, within 35 days prior to Day 0.
  12. To be assessed at Day 0: Has used vitamins or dietary/herbal supplements within 7 days prior to Day 0.
  13. Routinely uses oral analgesics ≥ 5 times per week.
  14. Has any disease or condition that may cause abnormal alterations in body temperature.
  15. Has a clotting/bleeding disorder and is at risk of excessive bleeding.
  16. Has evidence or history of a clinically significant laboratory abnormality or hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, immunologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within the last 5 years that, in the PI's or medically qualified designee's opinion, may jeopardize the subject's safety or well-being or the integrity of the study.
  17. Has any clinically significant gastrointestinal disorder/disease/condition or is taking medication for any such disorder/disease/condition that, per the PI's or medically qualified designee's judgement, could affect the absorption, metabolism, or excretion of the study medication.
  18. Has a history of recurrent, acute, or chronic infections of any type or any findings suggestive of occult infection, such as tuberculosis, sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection, etc. Also excluded are subjects with frequent (more than 3 outbreaks per year), recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the PI or medically qualified designee to have the potential for exacerbation by participation in the study.
  19. Heart rate \< 50 bpm or is deemed to be at high risk of syncope and/or hypotension per the clinical judgment of the PI or medically qualified designee at Visit 1, on Day 0, or on Day 1.
  20. Supine blood pressure \<90 or >140 mmHg (systolic) or \<50 or >90 mmHg (diastolic), following at least 5 minutes of supine rest, as assessed at Visit 1, on Day 0, or on Day 1.
  21. Supine 12-lead ECG demonstrating >450 msec or a QRS interval >120 msec at Visit 1 or on Day 1 prior to endotoxinadministration.
  22. Other severe, acute or chronic medical or psychiatric condition(s) or laboratory abnormality(ies) that may increase the risk associated with study participation or ISM administration or may interfere with the interpretation of study results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
292 participants (estimated)

Study arms

  • Experimental
    Acetaminophen 650 mg/Naproxen Sodium 220 mg

    Acetaminophen 650 mg/Naproxen Sodium 220 mg (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg).

    Drug: Acetaminophen 650 mg/Naproxen Sodium 220 mg

  • Placebo comparator
    Placebo

    Placebo (administered as two tablets of placebo).

    Drug: Placebo tablet

Interventions

  • DrugAcetaminophen 650 mg/Naproxen Sodium 220 mg

    The IP is to be taken as a single dose (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg) orally with 180 mL of room temperature water.

  • DrugPlacebo tablet

    The placebo is to be taken as a single dose (administered as two tablets of placebo) orally with 180 mL of room temperature water.

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of Temperature Differences (WSTD) from 0 to 8 hours (WSTD 0-8)

    WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330,360,390,420,450, and 480 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 8 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours).

    Time frame: Baseline (0 hour) up to 8 hours

  2. Time-weighted Sum of Temperature Differences (WSTD) from 0 to 12 hours (WSTD 0-12)

    WSTD 0-12 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570,600,630,660,690,and 720 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 12 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5 , and 12 hours).

    Time frame: Baseline (0 hour) up to 12 hours

Secondary outcomes

  1. Time-weighted Sum of Temperature Differences (WSTD) from 0 to 6 hours (WSTD 0-6)

    WSTD 0-6 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330, and 360 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 6 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours).

    Time frame: Baseline (0 hour) up to 6 hours

  2. Time-weighted Sum of Temperature Differences (WSTD) from 0 to 10 hours (WSTD 0-10)

    WSTD 0-10 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570, and 600 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 10 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 hours).

    Time frame: Baseline (0 hour) up to 10 hours

  3. Subject Global Evaluation Questionnaire

    Participants will be asked to evaluate the performance of the investigational study material (ISM) using a 5-point Likert scale : 0= poor , 1=fair , 2=good , 3=very good , 4=excellent

    Time frame: Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).

  4. Time to first use of rescue medication

    Time to rescue medication (other than study treatment) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.

    Time frame: Baseline (0 hour) to 12 hours

  5. Proportion of subjects using rescue medication from 0 to 12 hours

    Time frame: Baseline (0 hour) to 12 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2026
First posted
Nov 19, 2026
StartActual
Oct 20, 2026
Primary completionEst.
Oct 29, 2027
CompletionEst.
Oct 29, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948811
Lead sponsor
Kenvue Brands LLC
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Oct 20, 2026
Primary completion
Oct 29, 2027 (estimated)
Completion
Oct 29, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Kenvue GCO Clinical Mailbox
Contact
KenvueClinical_KV@kenvue.com
18779295131
Tobore Tobore
study director · Kenvue Brands LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion